Related Experiment Video
Updated: Jun 12, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review
Jamile Barboza de Oliveira1, Saulo Brito Silva2, Igor Lima Fernandes3
1Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Abstract:
Despite treatment advances through immunotherapies, including anti-PD-1/PD-L1 therapies, the overall prognosis of non-small cell lung cancer (NSCLC) patients remains poor, underscoring the need for novel approaches that offer long-term clinical benefit. This review examined the literature on the subject over the past 20 years to provide an update on the evolving landscape of dendritic cell-based immunotherapy to treat NSCLC, highlighting the crucial role of dendritic cells (DCs) in immune response initiation and regulation. These cells encompass heterogeneous subsets like cDC1s, cDC2s, and pDCs, capable of shaping antigen presentation and influencing T cell activation through the balance between the Th1, Th2, and Th17 profiles and the activation of regulatory T lymphocytes (Treg). The intricate interaction between DC subsets and the high density of intratumoral mature DCs shapes tumor-specific immune responses and impacts therapeutic outcomes. DC-based immunotherapy shows promise in overcoming immune resistance in NSCLC treatment. This article review provides an update on key clinical trial results, forming the basis for future studies to characterize the role of different types of DCs in situ and in combination with different therapies, including DC vaccines.
Insights
Dendritic cell (DC) immunotherapy offers a promising approach to enhance anti-tumor immunity in non-small cell lung cancer (NSCLC). Further research into DC subsets and their combination therapies is crucial for improving patient outcomes.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Non-small cell lung cancer (NSCLC) prognosis remains poor despite immunotherapy advances.
- Dendritic cells (DCs) are critical for initiating and regulating immune responses.
- Understanding DC subsets (cDC1, cDC2, pDCs) is key to modulating T cell activation and anti-tumor immunity.
Purpose of the Study:
- To review the evolving landscape of dendritic cell-based immunotherapy for NSCLC.
- To highlight the role of diverse DC subsets in shaping anti-tumor immune responses.
- To update on clinical trial results and guide future research directions.
Main Methods:
- Comprehensive literature review of studies over the past 20 years.
- Analysis of the role of different dendritic cell subsets in NSCLC immunity.
- Examination of clinical trial data for DC-based immunotherapies.
Main Results:
- Dendritic cells orchestrate immune responses by influencing T cell profiles (Th1, Th2, Th17) and regulatory T cells (Treg).
- Intratumoral mature DC density impacts tumor-specific immunity and therapeutic outcomes.
- DC-based immunotherapy demonstrates potential in overcoming NSCLC immune resistance.
Conclusions:
- Dendritic cell immunotherapy is a promising strategy for NSCLC treatment.
- Further characterization of DC subsets in situ and their combination with therapies like DC vaccines is warranted.
- Optimizing DC-based strategies may improve long-term clinical benefit for NSCLC patients.
More Related Videos
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
